Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma
Tóm tắt
Osteosarcoma is the most frequent primary bone tumor with poor prognosis. Through RNA-sequencing of 100,987 individual cells from 7 primary, 2 recurrent, and 2 lung metastatic osteosarcoma lesions, 11 major cell clusters are identified based on unbiased clustering of gene expression profiles and canonical markers. The transcriptomic properties, regulators and dynamics of osteosarcoma malignant cells together with their tumor microenvironment particularly stromal and immune cells are characterized. The transdifferentiation of malignant osteoblastic cells from malignant chondroblastic cells is revealed by analyses of inferred copy-number variation and trajectory. A proinflammatory FABP4+ macrophages infiltration is noticed in lung metastatic osteosarcoma lesions. Lower osteoclasts infiltration is observed in chondroblastic, recurrent and lung metastatic osteosarcoma lesions compared to primary osteoblastic osteosarcoma lesions. Importantly, TIGIT blockade enhances the cytotoxicity effects of the primary CD3+ T cells with high proportion of TIGIT+ cells against osteosarcoma. These results present a single-cell atlas, explore intratumor heterogeneity, and provide potential therapeutic targets for osteosarcoma.
Từ khóa
Tài liệu tham khảo
Pingping, B. et al. Incidence and Mortality of Sarcomas in Shanghai, China, During 2002–2014. Front. Oncol. 9, 662 (2019).
Lancia, C. et al. A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup. Cancer Chemother. Pharmacol. 83, 951–962 (2019).
Rosenberg, A. E. WHO Classification of Soft Tissue and Bone, fourth edition: summary and commentary. Curr. Opin. Oncol. 25, 571–573 (2013).
Mutsaers, A. J. & Walkley, C. R. Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells? Bone 62, 56–63 (2014).
Ciernik, I. F. et al. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer 117, 4522–4530 (2011).
Duggan, M. A. et al. The surveillance, epidemiology, and end results (SEER) program and pathology: toward strengthening the critical relationship. Am. J. Surg. Pathol. 40, e94–e102 (2016).
Zhao, J. et al. Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy. Cancer Lett. 474, 158–167 (2020).
Suehara, Y. et al. Clinical genomic sequencing of pediatric and adult osteosarcoma reveals distinct molecular subsets with potentially targetable alterations. Clin. Cancer Res. 25, 6346–6356 (2019).
Tang, F. et al. Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma. J. Orthop. Res. 37, 789–798 (2019).
Wang, D. et al. Multiregion sequencing reveals the genetic heterogeneity and evolutionary history of osteosarcoma and matched pulmonary metastases. Cancer Res. 79, 7–20 (2019).
Zhang, J. et al. Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment. Precis. Clin. Med. 1, 29–48 (2018).
Le Cesne, A. et al. Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. Eur. J. Cancer 119, 151–157 (2019).
Thanindratarn, P. et al. Advances in immune checkpoint inhibitors for bone sarcoma therapy. J. Bone Oncol. 15, 100221 100221 (2019).
Tawbi, H. A. et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 18, 1493–1501 (2017).
Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189–196 (2016).
Mereu, E. et al. Benchmarking single-cell RNA-sequencing protocols for cell atlas projects. Nat. Biotechnol. 38, 747–755 (2020).
Lee, H. W. et al. Single-cell RNA sequencing reveals the TME and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. Genome Med. 12, 47 (2020).
Tirosh, I. et al. Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature 539, 309–313 (2016).
Meng, M. et al. S100 calcium binding protein A11 (S100A11) promotes the proliferation, migration and invasion of cervical cancer cells, and activates Wnt/β-catenin signaling. Onco. Targets Ther. 12, 8675–8685 (2019).
Wang, L. et al. S100A10 silencing suppresses proliferation, migration and invasion of ovarian cancer cells and enhances sensitivity to carboplatin. J. Ovarian. Res. 12, 113 (2019).
Lv, Z. et al. Disruption of the c-Myc/miR-200b-3p/PRDX2 regulatory loop enhances tumor metastasis and chemotherapeutic resistance in colorectal cancer. J. Transl. Med. 15, 257 (2017).
Fejzo, M. S. et al. Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi. Genes Chromosomes Cancer 56, 589–597 (2017).
Sayles, L. C. et al. Genome-Informed Targeted Therapy for Osteosarcoma. Cancer Discov. 9, 46–63 (2019).
Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396–1401 (2014).
Puram, S. V. et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell 171, 1611–1624.e1624 (2017).
Atiye, J. et al. Gene amplifications in osteosarcoma-CGH microarray analysis. Genes Chromosomes Cancer 42, 158–163 (2005).
Lu, X. Y. et al. Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma. Mol. Cancer Res. 6, 937–946 (2008).
Durante, M. A. et al. Single-cell analysis reveals new evolutionary complexity in uveal melanoma. Nat. Commun. 11, 496 (2020).
Aghajanian, P. et al. Epiphyseal bone formation occurs via thyroid hormone regulation of chondrocyte to osteoblast transdifferentiation. Sci. Rep. 7, 10432 (2017).
Wong, S. A. et al. Microenvironmental regulation of chondrocyte plasticity in endochondral repair-a new Frontier for developmental engineering. Front. Bioeng. Biotechnol. 6, 58 (2018).
Saelens, W. et al. A comparison of single-cell trajectory inference methods. Nat. Biotechnol. 37, 547–554 (2019).
Cannoodt, R. et al. SCORPIUS improves trajectory inference and identifies novel modules in dendritic cell development. Nat. Immunol. 7, 718–726 (2016).
Akiyama, T. et al. Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway. Mol. Cancer Ther. 7, 3461–3469 (2008).
Sinha, P., Clements, V. K., Bunt, S. K., Albelda, S. M. & Ostrand-Rosenberg, S. et al. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 179, 977–983 (2007).
Sawant, A. et al. Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer Res. 73, 672–682 (2013).
Bozec, A. et al. Fra-2/AP-1 controls bone formation by regulating osteoblast differentiation and collagen production. J. Cell. Biol. 190, 1093–1106 (2010).
Shi, T. et al. Gene expression profiles of peripheral blood monocytes in osteoarthritis and analysis of differentially expressed genes. Biomed. Res. Int. 2019, 4291689 (2019).
Zheng, Y. et al. Mesenchymal stem cells in the osteosarcoma microenvironment: their biological properties, influence on tumor growth, and therapeutic implications. Stem. Cell. Res. Ther. 9, 22 (2018).
Stenger, E. O. et al. Bone marrow-derived mesenchymal stromal cells from patients with sickle cell disease display intact functionality. Biol. Blood Marrow Transplant. 23, 736–745 (2017).
Shen, W. C. et al. Methylation and PTEN activation in dental pulp mesenchymal stem cells promotes osteogenesis and reduces oncogenesis. Nat. Commun. 10, 2226 (2019).
Grünberg, J. R. et al. The novel secreted adipokine WNT1-inducible signaling pathway protein 2 (WISP2) is a mesenchymal cell activator of canonical WNT. J. Biol. Chem. 289, 6899–6907 (2014).
Lu, J. et al. IRX1 hypomethylation promotes osteosarcoma metastasis via induction of CXCL14/NF-κB signaling. J. Clin. Invest. 125, 1839–1856 (2015).
Wang, M. et al. Molecular structure, expression, and functional role of Clec11a in skeletal biology and cancers. J. Cell. Physiol. 235, 6357–6365 (2020).
Pelon, F. et al. Cancer-associated fibroblast heterogeneity in axillary lymph nodes drives metastases in breast cancer through complementary mechanisms. Nat. Commun. 11, 404 (2020).
Cortini, M. et al. Mesenchymal stroma: role in osteosarcoma progression. Cancer Lett. 405, 90–99 (2017).
Liu, B. et al. Prognostic value of inflammation-based scores in patients with osteosarcoma. Sci. Rep. 6, 39862 (2016).
Wang, D. et al. The role of chemokines in intestinal inflammation and cancer. Curr. Opin. Pharmacol. 9, 688–696 (2009).
Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163–172 (2019).
Rodríguez-Fernández, JoséLuis & Criado-García, Olga The chemokine receptor CCR7 uses distinct signaling modules with biased functionality to regulate dendritic cells. Front. Immunol. 15, 11:528 (2020).
Anderson, D. A. et al. Models of dendritic cell development correlate ontogeny with function. Adv. Immunol. 143, 99–119 (2019).
Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321–330 (2017).
Smeland, S. et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur. J. Cancer 109, 36–50 (2019).
Harari, A. et al. Distinct profiles of cytotoxic granules in memory CD8 T cells correlate with function, differentiation stage, and antigen exposure. J. Virol. 83, 2862–2871 (2009).
Lozano, E. et al. Nectin-2 expression on malignant plasma cells is associated with better response to TIGIT blockade in multiple myeloma. Clin. Cancer Res. 26, 4688–4698 (2020).
Ohmura, H. et al. OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody. Br. J. Cancer 122, 1507–1517 (2020).
Grossman, W. J. et al. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21, 589–601 (2004).
Takanori, S. O. & Naoto, Ishii The TNF-TNFR family of co-signal molecules. Adv. Exp. Med. Biol. 1189, 53–84 (2019).
Shimizu, K. et al. NK and NKT cell-mediated immune surveillance against hematological malignancies. Cancers 12, 817 (2020).
Holder, K. A. et al. TIGIT blockade: a multipronged approach to target the HIV reservoir. Front. Cell. Infect. Microbiol. 10, 175 (2020).
Such, L. et al. Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy. J. Clin. Invest. 130, 4266–4281 (2020).
Reimann, E. et al. Whole exome sequencing of a single osteosarcoma case–integrative analysis with whole transcriptome RNA-seq data. Hum. Genomics. 8, 20 (2014).
Bousquet, M. et al. Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations. Ann. Oncol. 27, 738–744 (2016).
Walsh, M. C. et al. Updating osteoimmunology: regulation of bone cells by innate and adaptive immunity. Nat. Rev. Rheumatol. 14, 146–156 (2018).
Ali, N. M. et al. Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone. J. Pathol. 247, 166–176 (2019).
Wang, D. W. et al. A novel mechanism of mTORC1-mediated serine/glycine metabolism in osteosarcoma development. Cell. Signal. 29, 107–114 (2017).
Tsagozis, P. et al. Treatment outcome of patients with chondroblastic osteosarcoma of the limbs and pelvis. Bone Jt. J. 101-b, 739–744 (2019).
Hojo, H. & Ohba, S. Insights into gene regulatory networks in chondrocytes. Int. J. Mol. Sci. 20, 6324 (2019).
Kittaka, M. et al. Cherubism mice also deficient in c-Fos exhibit inflammatory bone destruction executed by macrophages that express MMP14 despite the absence of TRAP+ osteoclasts. J. Bone Miner. Res. 33, 167–181 (2018).
Yin, Q. et al. Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis. Proc. Natl Acad. Sci. USA 113, E4601–E4609 (2016).
Li, H. et al. Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. Blood 116, 210–217 (2010).
Benasciutti, E. et al. MHC class II transactivator is an in vivo regulator of osteoclast differentiation and bone homeostasis co-opted from adaptive immunity. J. Bone Miner. Res. 29, 290–303 (2014).
Walzer, S. M. et al. Vascularization of primary and secondary ossification centres in the human growth plate. Bmc. Dev. Biol. 14, 36 (2014).
Sawant, A. & Ponnazhagan, S. Myeloid-derived suppressor cells as osteoclast progenitors: a novel target for controlling osteolytic bone metastasis. Cancer Res. 73, 4606–4610 (2013).
Corre, I. et al. The osteosarcoma microenvironment: a complex but targetable ecosystem. Cells 15 9, 976 (2020).
Ferguson, A. & Chen, K. Analysis of transcriptional profiling of immune cells at the single-cell level. Methods Mol. Biol. 2111, 47–57 (2020).
Yang, D. & Wan, Y. Molecular determinants for the polarization of macrophage and osteoclast. Semin. Immunopathol. 41, 551–563 (2019).
Davis, K. L. et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 21, 541–550 (2020).
Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15, 486–499 (2015).
Chiu, D. K. et al. Hepatocellular carcinoma cells up-regulate PVRL1, stabilizing PVR and inhibiting the cytotoxic T-cell response via TIGIT to mediate tumor resistance to PD1 inhibitors in mice. Gastroenterology 159, 609–623 (2020).
Hoogi, S. et al. A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function. J. Immunother. Cancer 7, 243 (2019).
Zhang, Q. et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat. Immunol. 19, 723–732 (2018).
Stamm, H. et al. Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer. Oncoimmunology 8, e1674605 (2019).
Link, M. P. et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N. Engl. J. Med. 314, 1600–1606 (1986).
Butler, A. et al. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420 (2018).
McGinnis, C. S. et al. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell. Syst. 8, 329–337.e324 (2019).
Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289–1296 (2019).
Yu, G. et al. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284–287 (2012).
Cillo, A. R. et al. Immune landscape of viral- and carcinogen-driven head and neck cancer. Immunity 52, 183–199.e189 (2020).
Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739–1740 (2011).
Chung, W. et al. Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nat. Commun. 8, 15081 (2017).
Trapnell, C. et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat. Biotechnol. 32, 381–386 (2014).